PYXS Pyxis Oncology, Inc.
Healthcare$1.63-16.84%ClosedMarket Cap: $103.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.98
P/S
8.96
EV/EBITDA
-1.69
DCF Value
$1.73
FCF Yield
-53.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.8%
Operating Margin
-619.6%
Net Margin
-589.8%
ROE
-135.6%
ROA
-127.1%
ROIC
-173.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-24.4M | $-23.3M | $— | — |
| Q4 null | $11.0M | 103.9% | $-18.3M | $-18.1M | $— | — |
| FY null | $13.9M | 82.8% | $-84.4M | $-79.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-23.5M | $-22.0M | $— | — |
| Q2 null | $2.8M | 100.0% | $-19.8M | $-18.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-22.9M | $-21.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-40.1M | $-35.6M | $— | — |
| FY null | $16.1M | 97.1% | $-89.5M | $-77.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-23.8M | $-21.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-20.0M | $-17.3M | $— | — |
| Q1 null | $16.1M | 97.1% | $-5.6M | $-3.3M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-17.8M | $-15.6M | $-0.35 | — |